Targeted CD73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
US12024565B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 7, 2019 |
| Grant date | Jul 2, 2024 |
| Priority date | — |
| Expiry date | Oct 30, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed by the present invention are a targeted CD73 antibody and an antibody-drug conjugate (ADC), and a preparation method therefor and application thereof. Further disclosed is a method for preparing the described monoclonal antibody and ADC. The monoclonal antibody and the corresponding ADC disclosed by the present invention can be efficiently and highly specifically combined with purified CD73 protein and CD73 on the surfaces of multiple tumor cells to block the catalytic activity of CD73 enzyme, and have high affinity, low immunogenicity and significant anti-tumor effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.